Stocks · News reference
Niki BioSolutions Subsidiary DiamiR Biosciences Receives NYSDOH Approval for Expanded APOE Genotyping Specimen Types
Niki BioSolutions, Inc. announced that its subsidiary, DiamiR Biosciences Corp., received approval from the New York State Department of Health to expand the specimen types for its APOE Genotyping test.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Niki BioSolutions Subsidiary DiamiR Biosciences Signs APOE Genotyping Agreement with Charter Research
Niki BioSolutions, Inc. announced that its subsidiary, DiamiR Biosciences, has entered into an agreement to provide apolipoprotein E (APOE) genotyping services for Charter Research.
Niki BioSolutions' DiamiR Biosciences Subsidiary To Perform Apolipoprotein E Genotyping On Plasma Samples From Global Alzheimer’s Platform Foundation Bio-Hermes-002 Trial Group
Niki BioSolutions, Inc. (NASDAQ: NIKI) ("Niki" or the "Company"), a clinical-stage life sciences company focused on unmet medical needs and genomic and biomarker testing solutions, today announced that